On August 21, the FDA approved Ionis Pharmaceuticals' breakthrough drug DAWNZERA™ (donidalorsen), the first RNA-targeted therapy for hereditary angioedema (HAE).
This approval authorizes DAWNZERA for preventing HAE attacks in adults and children aged 12 years and older. HAE is a rare, potentially life-threatening genetic disorder characterized by severe recurrent swelling in various body parts, including the hands, feet, genitals, abdomen, face, and/or throat. Approximately 7,000 people are estimated to be affected by this condition in the United States.
DAWNZERA is a LICA (Ligand-Coupled Anticidon) drug specifically designed to target plasma kininsokines (PKK), a protein crucial for activating inflammatory mediators associated with acute HAE attacks. By precisely targeting and silencing PKK mRNA expression, DAWNZERA inhibits the synthesis of pathogenic proteins at their source, blocks the signaling pathways triggering HAE episodes, and achieves precise disruption of the HAE attack cascade.
The formulation is an 80mg subcutaneous injection that is self-administered using a auto-injector. The recommended dosing regimen of every 4 weeks (Q4W) or every 8 weeks (Q8W) makes it the longest-dosing interval currently available in HAE treatment, significantly improving patient convenience and treatment adherence.
The FDA's approval decision was based primarily on the results of the pivotal Phase III OASIS-HAE study. This global, multicenter, randomized, double-blind, placebo-controlled clinical trial achieved its primary endpoint.
The study showed that patients receiving subcutaneous DAWNZERA injections every four weeks had a significant 81% reduction in the average monthly incidence of HAE over 24 weeks compared to placebo.
The average incidence rate was reduced by 87% at the time of assessment from the second dose (key secondary endpoint). Additionally, DAWNZERA reduced moderate to severe HAE attacks by approximately 90% over 24 weeks when measured from the second dose.
These results are further supported by the ongoing OASISplus Open Label Extension (OLE) study, where patients receiving DAWNZERA every eight weeks demonstrated efficacy over time comparable to the four-week regimen.
In the OLE study, both dosing regimens achieved a 94% reduction in total average incidence from baseline after one year.
Earlier phase II OLE studies showed that the overall sustained incidence of HAE attacks decreased by an average of 96%, with a sustained efficacy of up to three years, demonstrating excellent long-term stability and tolerability.
The OASISplus study also included a conversion cohort that evaluated the switch to DAWNZERA every four weeks in patients who had previously received lanadelumab, C1-esterase inhibitors, or berotralstat for at least 12 weeks.
After switching to DAWNZERA, the average HAE incidence rate was further reduced by 62% compared with prior prophylactic treatment.
No significant increase in breakthrough seizures was observed during the transition period. A total of 84% of surveyed patients preferred DAWNZERA over their previous preventive treatment, citing better disease control, shorter dosing times, and reduced injection site pain or reactions.
In the CROSS clinical study, DAWNZERA demonstrated favorable safety and tolerability profiles. The most common adverse reactions (occurring in ≥5% of participants) included injection site reactions, upper respiratory tract infections, urinary tract infections, and abdominal discomfort. Most adverse events were mild to moderate in severity, with no reports of treatment-related serious adverse events.
In addition to significant clinical efficacy, DAWNZERA also significantly improved patients' quality of life. According to data from the OASISplus study, patients receiving treatment every four weeks and every eight weeks showed improvements of 28 and 24 points in Angioedema Control test scores, respectively.
Ionis Pharmaceuticals has established commercial partnerships with multiple companies. Otsuka Pharmaceutical holds the exclusive commercialization rights for Donidalorsen in Europe and the Asia-Pacific region, including Japan. The European Medicines Agency (EMA) has also accepted its marketing application, signaling accelerated global approval. Ionis announced that DAWNZERA will be launched in the United States within the coming days. To support patients and healthcare providers, Ionis offers a range of services through the Ionis Every Step™ program, including patient education, insurance assistance, and access to digital resources.
Regarding pricing, DAWNZERA was reportedly initially priced at approximately $57,462 per dose in the U.S. market. With six injections required annually, the annual treatment cost approaches $350,000. While Ionis has introduced free trial programs and patient support initiatives, the long-term success of this innovative drug hinges on its inclusion in public insurance coverage and commercial insurers' willingness to pay for it.
Disclaimer: This article is only for the purpose of knowledge exchange and sharing, and does not involve commercial publicity, and does not serve as relevant medical guidance or medication advice. If there is any infringement of the article, please contact us for deletion.
Our products are recommended:
1.17247-58-4 https://www.bicbiotech.com/product_detail.php?id=6337
2.2089386-33-2 https://www.bicbiotech.com/product_detail.php?id=6338
3.275818-95-6 https://www.bicbiotech.com/product_detail.php?id=6339
4.1208078-13-0 https://www.bicbiotech.com/product_detail.php?id=6340
5.3388-79-2 https://www.bicbiotech.com/product_detail.php?id=6341
